In a nutshell
This study looked at the effect of removing an alpha 1-blocker (A1B) from an A1B plus 5 alpha-reductase inhibitor (5ARI) combination therapy on urinary symptoms due to benign prostatic hyperplasia (BPH – an enlarged prostate). The study found that removing an A1B from combination therapy did not affect urinary and bladder symptoms.
Some background
Combination therapy of an A1B and a 5ARI is a common treatment for urinary symptoms of BPH. These drugs target receptors in the bladder. However, more drug treatment may have more side effects. It is necessary to research if removing A1B from combination therapy will affect bladder and urinary symptoms.
Methods & findings
132 patients on combination therapy of silodosin (Rapaflo, an AIB) and dutasteride (Avodart, a 5ARI) were studied. 66 (50%) patients stopped silodosin treatment. 66 (50%) remained on combination therapy. Patients were followed up for 12 months.
No differences in symptoms were reported between the 2 groups. Bladder storage was decreased in the monotherapy group in overweight patients.
The bottom line
The study found that switching from combination therapy to monotherapy by removing an alpha 1-blocker did not worsen bladder symptoms.
The fine print
The study of the effect of other drug therapies in the same class may be useful.
What’s next?
Talk to your doctor about removing your a1-blocker if you are on combination therapy.
Published By :
Journal of Urology
Date :
May 09, 2017
